Hesperos, Inc.
Hesperos is a leading company in human-on-a-chip research, providing advanced multi-organ microphysiological systems for drug discovery, disease modeling, and safety testing. With over 20 years of expertise, they develop physiologically realistic models that offer unprecedented preclinical insights, aiming to accelerate drug development, reduce animal testing, and target both rare and common diseases.
Industries
Nr. of Employees
small (1-50)
Hesperos, Inc.
12501 Research Pkwy, Suite 100, Orlando, FL 32826
Products
Configurable multi-organ microphysiological platform
An integrated, reconfigurable in vitro platform that links multiple human tissue modules in a low-volume, serum-free, pumpless recirculating system with noninvasive functional readouts for preclinical testing and translational studies.
Configurable multi-organ microphysiological platform
An integrated, reconfigurable in vitro platform that links multiple human tissue modules in a low-volume, serum-free, pumpless recirculating system with noninvasive functional readouts for preclinical testing and translational studies.
Services
Contract research services to evaluate compound efficacy, off-target toxicity, metabolite effects, and therapeutic index using configurable multi-organ in vitro platforms.
Design and build of bespoke multi-organ models incorporating selected organ and barrier tissues, patient-derived or iPSC cells, and bespoke assay metrics for specific research questions.
Computational modeling services that combine experimental concentration measurements and fluid dynamics to derive PK-PD relationships and extrapolate in vitro results toward in vivo outcomes.
Analytical measurement of parent compounds and metabolites in system media and compartments using HPLC–mass spectrometry to support PK profiling and metabolite identification.
Contract research services to evaluate compound efficacy, off-target toxicity, metabolite effects, and therapeutic index using configurable multi-organ in vitro platforms.
Design and build of bespoke multi-organ models incorporating selected organ and barrier tissues, patient-derived or iPSC cells, and bespoke assay metrics for specific research questions.
Computational modeling services that combine experimental concentration measurements and fluid dynamics to derive PK-PD relationships and extrapolate in vitro results toward in vivo outcomes.
Analytical measurement of parent compounds and metabolites in system media and compartments using HPLC–mass spectrometry to support PK profiling and metabolite identification.
Expertise Areas
- Microphysiological systems development
- In vitro disease and translational modeling
- Preclinical safety and efficacy testing using linked tissue platforms
- PK/PD, PBPK and translational computational modeling
Key Technologies
- Pumpless rocking microfluidics
- Microelectrode arrays (MEA)
- Microcantilever force sensors
- Induced pluripotent stem cell (iPSC) differentiation
News & Updates
Visit us at Booth #301! Hesperos Presenters James Hickman, PhD Lawrence Florin Nate Post Rocky Brighton Christopher Long, PhD Joseph Ciurca Aakash Patel Andrew Antolic, PhD Brittany Robaina-Caicedo Brianna Botlick About MPS ...
We will be a part of the Florida Pavilion at Booth #778. Stop by and see us! About the BIO International Convention: BIO is the world’s largest advocacy association representing biotechnology companies, ...
Panelist James Hickman, PhD, Hesperos Co-Founder and Chief Scientist June 25, 11:00 AM EST About Replacing Animal Testing: Are In Vitro Models Ready for Prime ...
A scientific article discussing personalized treatment approaches for Charcot-Marie-Tooth disease using organ-on-a-chip models.
Hesperos is the first tissue chip company to reach the Phase IIb level of NIH funding, validating its technology for regulatory acceptance.
Visit us at Booth #301! Hesperos Presenters James Hickman, PhD Lawrence Florin Nate Post Rocky Brighton Christopher Long, PhD Joseph Ciurca Aakash Patel Andrew Antolic, PhD Brittany Robaina-Caicedo Brianna Botlick About MPS ...
We will be a part of the Florida Pavilion at Booth #778. Stop by and see us! About the BIO International Convention: BIO is the world’s largest advocacy association representing biotechnology companies, ...
Panelist James Hickman, PhD, Hesperos Co-Founder and Chief Scientist June 25, 11:00 AM EST About Replacing Animal Testing: Are In Vitro Models Ready for Prime ...
A scientific article discussing personalized treatment approaches for Charcot-Marie-Tooth disease using organ-on-a-chip models.
Hesperos is the first tissue chip company to reach the Phase IIb level of NIH funding, validating its technology for regulatory acceptance.